VERAXA Biotech AG (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 that cover its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company’s BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. This approach aims to reduce off-target effects, a common challenge in oncology. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
The expansion of the patent portfolio marks a significant step for VERAXA as it seeks to establish a competitive edge in the rapidly evolving field of cancer immunotherapy. By securing broad intellectual property protection, the company is positioning itself to fend off competitors and attract potential partners interested in its innovative platforms. The patents cover not only the BiTAC technology but also key enabling technologies that could be applicable across multiple therapeutic modalities.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s pipeline includes bispecific T cell engagers and bispecific ADCs, which are designed to harness the immune system to target and destroy cancer cells more precisely.
The news is important because it underscores VERAXA’s commitment to building a robust intellectual property estate that could support long-term growth and innovation. As the company moves its programs toward clinical development, a strong patent portfolio will be critical for securing investment and partnerships. For more information, visit the company’s newsroom at http://ibn.fm/VRXA.
